PROBES FOR IMAGING HUNTINGTIN PROTEIN

Abstract

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

##STR00001##

Claims

1. A compound of Formula I, or a pharmaceutically acceptable salt thereof, ##STR00038## wherein Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are independently chosen from CH and N, provided that at least two of Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are CH; R.sub.1 is chosen from aryl, heteroaryl, and heterocycloalkenyl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, heteroaryl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino; L.sub.1 is chosen from O and NR.sub.4; R.sub.4 is chosen from hydrogen and lower alkyl; L.sub.2 is (CH.sub.2).sub.m where m is 0, 1, or 2; and R.sub.2 is chosen from hydrogen, aryl, aryl substituted with hydroxyl or lower alkoxy, heteroaryl, and heteroaryl substituted with hydroxyl or lower alkoxy, R.sub.5 is chosen from lower alkyl, lower alkoxy, halo, and oxo (as a substituent on the heterocycloalkyl ring); and n is 0 or 1.

2. The compound of claim 1, wherein R.sub.1 is phenyl optionally substituted with one or two groups independently chosen from cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

3. The compound of claim 2, wherein R.sub.1 is phenyl optionally substituted with one or two groups independently chosen from cyano, methyl, and methyl substituted with amino, (alkyl)amino or (dialkyl)amino.

4. The compound of claim 3, wherein R.sub.1 is 2-cyanophenyl.

5. The compound of claim 1, wherein R.sub.1 is heteroaryl optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

6. The compound of claim 5, wherein R.sub.1 is chosen from pyridine-4-yl, pyridine-2-yl, pyridine-3-yl, pyrimidine-4-yl, 1,2-dihydropyridin-2-one-3-yl, 1H-indazole-4-yl, and 1H-indazole-7-yl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

7. The compound of claim 6, wherein R.sub.1 is chosen from pyridine-4-yl, pyridine-2-yl, pyridine-3-yl, and pyrimidine-4-yl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

8. The compound of claim 6, wherein R.sub.1 is chosen from 5-cyano-pyrimidine-4-yl, pyridine-4-yl, 5-bromo-1,2-dihydropyridin-2-one-3-yl, 3-acetamido-pyridine-4-yl, 2-acetamido-pyridine-6-yl, 3-cyano-pyridine-4-yl, 3-cyano-pyridine-6-yl, 3-bromo-pyridine-4-yl, 3-bromo-pyridine-2-yl, 3-cyano-pyridine-2-yl, 3-fluoro-pyridine-4-yl, 2-cyano-pyridine-4-yl, 4-cyano-pyridine-3-yl, and 3-ethynyl-pyridine-4-yl.

9. The compound of claim 8, wherein R.sub.1 is pyridine-4-yl, 5-cyano-pyrimidine-4-yl, or 3-cyano-pyridine-4-yl.

10. The compound of claim 1, wherein R.sub.1 is heterocycloalkenyl optionally substituted with lower alkyl.

11. The compound of claim 10, wherein R.sub.1 is 2,3-dihydropyridazine-6-yl optionally substituted with lower alkyl.

12. The compound of claim 1, wherein L.sub.1 is O.

13. The compound of claim 12, wherein m is 1.

14. The compound of claim 12, wherein R.sub.2 is chosen from hydrogen, aryl, aryl substituted with hydroxyl or lower alkoxy, heteroaryl, and heteroaryl substituted with hydroxyl or lower alkoxy.

15. The compound of claim 14, wherein R.sub.2 is chosen from hydrogen, phenyl, pyridine-2-yl, pyrimidine-5-yl, pyrazin-2-yl, and pyrimidin-5-yl, each of which, other than hydrogen, is optionally substituted with hydroxyl or lower alkoxy.

16. The compound of claim 1, wherein Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are CH.

17. The compound of claim 1, wherein Z.sub.1 is N and Z.sub.2, Z.sub.3, and Z.sub.4 are CH.

18. The compound of claim 1, wherein Z.sub.2 is N and Z.sub.1, Z.sub.3, and Z.sub.4 are CH.

19. The compound of claim 1, wherein Z.sub.2 and Z.sub.4 are N and Z.sub.1 and Z.sub.3 are CH.

20. A compound, or a pharmaceutically acceptable salt thereof, chosen from: 2-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile; 2-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; 2-[5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile; 4-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; 4-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyrimidine-5-carbonitrile; 4-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyrimidine-5-carbonitrile; 4-{5-[(5-hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; 4-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile; 4-[5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile; 5-[(5-methoxypyrazin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindole; 4-[5-(benzyloxy)-2,3-dihydro-1H-isoindol-2-yl]pyrimidine-5-carbonitrile; 4-{5-[(5-hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyrimidine-5-carbonitrile; 6-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}-2-methyl-2,3-dihydropyridazin-3-one; and 5-[(5-methoxypyridin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one.

21.-31. (canceled)

Description

[0054] Compounds described herein include, but are not limited to, their optical isomers, racemates, and other mixtures thereof. In those situations, the single enantiomers or diastereoisomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high-pressure liquid chromatography (HPLC) column. The term “isomers” refers to different compounds that have the same molecular formula. The term “stereoisomers” refers to isomers that differ only in the way the atoms are arranged in space. The term “enantiomers” refers to stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The symbol “(±)” may be used to designate a racemic mixture where appropriate. The term “diastereoisomers” refers to stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (−) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.

[0055] Where compounds described herein exist in various tautomeric forms, the term “compound” includes all tautomeric forms of the compound. Such compounds also include crystal forms including polymorphs and clathrates. Similarly, the term “salt” includes all tautomeric forms and crystal forms of the compound. The term “tautomers” refers to structurally distinct isomers that interconvert by tautomerization. Tautomerization is a form of isomerization and includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. Prototropic tautomerization or proton-shift tautomerization involves the migration of a proton accompanied by changes in bond order, often the interchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1H)-one tautomers.

[0056] Pharmaceutically acceptable forms of the compounds recited herein include pharmaceutically acceptable salts, and mixtures thereof. In some embodiments, the compounds described herein are in the form of pharmaceutically acceptable salts.

[0057] “Pharmaceutically acceptable salts” include, but are not limited to salts with inorganic acids, such as hydrochlorate, phosphate, diphosphate, hydrobromate, sulfate, sulfinate, nitrate, and like salts; as well as salts with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, haloalkanoate such as trifluoroacetate, and alkanoate such as acetate, HOOC—(CH.sub.2).sub.n—COOH where n is 0-4, and like salts. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium, and ammonium. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare non-toxic pharmaceutically acceptable addition salts.

[0058] The term “administering”, as used herein in conjunction with a diagnostic agent, such as, for example, a positron-emitter labeled compound described herein, means administering directly into or onto a target tissue or to administer the diagnostic agent systemically to a patient whereby the diagnostic agent is used to image the tissue or a pathology associated with the tissue to which it is targeted. “Administering” a composition may be accomplished by injection, infusion, or by either method in combination with other known techniques.

[0059] The term “Curie” (Ci) is a unit of measurement of radioactivity. One Ci refers to that amount of any radioactive material that will decay at a rate of 3.7×10.sup.10 disintegrations per second. The term “milliCurie” (mCi) refers to 10.sup.−3 Curie. It is understood that the International System (SI) unit of radioactivity, the Becquerel, is equal to one disintegration/second. Thus one Becquerel=2.7×10.sup.−11 Curie.

[0060] The term “diagnostic imaging”, as used herein, refers to the use of electromagnetic radiation to produce images of internal structures of the human or animal body for the purpose of diagnosis.

[0061] The term “effective amount” of a compound, as used herein, is a predetermined amount calculated to achieve a desired effect such as an amount sufficient to enable the acquisition of a desired image of the target organ of an individual. In some instances the target organ is the brain.

[0062] The term “huntingtin protein” or “HTT protein”, as used herein, refers to the protein encoded by the human huntingtin gene (HTT gene) located on the short (p) arm of chromosome 4 at position 16.3. More precisely, the IT.sub.15 gene coding for the HTT protein is located from base pair 3,076,407 to base pair 3,245,686 on chromosome 4.

[0063] The term “HTT protein aggregate”, as used herein refers to an insoluble fibrous amyloid comprising mis-folded HTT protein molecules.

[0064] The term “β-amyloid aggregate”, as used herein refers to an insoluble fibrous amyloid comprising mis-folded β-amyloid protein molecules.

[0065] The term “imaging agent”, as used herein, refers to a compound as described herein labeled with one or more positron-emitting isotopes or radionuclides. A positron-emitter labeled compound need only be enriched with a detectable isotope to a degree that permits detection with a technique suitable for the particular application.

[0066] The term “pathologic process”, as used herein, refers to an altered endogenous biological process that may be associated with the aberrant production and/or functioning of proteins, peptides, RNA and other substances associated with such biological process.

[0067] The term “PET imaging”, as used herein, refers to the use of a positron-emitter labeled compound to produce images of internal structures of the human or animal body.

[0068] The term “pharmaceutical composition” refers to a composition comprising at least one imaging agent described herein, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, without limitation, a human). Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether a composition has a desired efficacious outcome based upon the needs of the artisan.

[0069] The term “positron-emitting radionuclide”, as used herein, refers to a radioactive isotope that exhibits particular type of radioactive decay referred to as β+ decay, in which a proton inside a radionuclide nucleus is converted into a neutron while releasing a positron and an electron neutrino (v.sub.e). Some examples of positron-emitting radionuclides include .sup.15O, .sup.13N, .sup.11C, .sup.18F, .sup.76Br, and .sup.124I. These radionuclides have half-lives of about 2, 10, 20, 110 minutes, 16 hours, and 4.2 days respectively.

[0070] The term “tomography”, as used herein, refers to a process of imaging by sections. The images may be looked at individually, as a series of two-dimensional slices or together, as a computer-generated three-dimensional representation.

[0071] Provided is an imaging agent comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof,

##STR00003##

[0072] wherein

[0073] Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are independently chosen from CH and N, provided that at least two of Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are CH;

[0074] R.sub.1 is chosen from aryl, heteroaryl, and heterocycloalkenyl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, heteroaryl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino;

[0075] L.sub.1 is chosen from O and NR.sub.4;

[0076] R.sub.4 is chosen from hydrogen and lower alkyl;

[0077] L.sub.2 is (CH.sub.2).sub.m where m is 0, 1, or 2; and

[0078] R.sub.2 is chosen from hydrogen, aryl, aryl substituted with hydroxyl or lower alkoxy, heteroaryl, and heteroaryl substituted with hydroxyl or lower alkoxy,

[0079] R.sub.5 is chosen from lower alkyl, lower alkoxy, halo, and oxo (as a substituent on the heterocycloalkyl ring); and

[0080] n is 0 or 1;

[0081] wherein the compound of Formula I, or a pharmaceutically acceptable salt there of, is labeled with one or more positron-emitting radionuclides

[0082] Also provided is an imaging agent comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof,

##STR00004##

[0083] wherein

[0084] Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are independently chosen from CH and N, provided that at least two of Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are CH;

[0085] R.sub.1 is chosen from aryl and heteroaryl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino;

[0086] L.sub.1 is chosen from O and NR.sub.4;

[0087] R.sub.4 is chosen from hydrogen and lower alkyl;

[0088] L.sub.2 is (CH.sub.2).sub.m where m is 0, 1, or 2; and

[0089] R.sub.2 is chosen from hydrogen, heteroaryl, and heteroaryl substituted with hydroxyl or lower alkoxy,

[0090] R.sub.5 is chosen from lower alkyl, lower alkoxy, and halo; and

[0091] n is 0 or 1;

[0092] wherein the compound of Formula I, or a pharmaceutically acceptable salt there of, is labeled with one or more positron-emitting radionuclides.

[0093] In some embodiments, R.sub.1 is phenyl optionally substituted with one or two groups independently chosen from cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

[0094] In some embodiments, R.sub.1 is phenyl optionally substituted with one or two groups independently chosen from cyano, methyl, and methyl substituted with amino, (alkyl)amino or (dialkyl)amino.

[0095] In some embodiments, R.sub.1 is 2-cyanophenyl.

[0096] In some embodiments, R.sub.1 is heteroaryl optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

[0097] In some embodiments, R.sub.1 is chosen from pyridine-4-yl, pyridine-2-yl, pyridine-3-yl, pyrimidine-4-yl, 1,2-dihydropyridin-2-one-3-yl, 1H-indazole-4-yl, and 1H-indazole-7-yl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

[0098] In some embodiments, R.sub.1 is chosen from pyridine-4-yl, pyridine-2-yl, pyridine-3-yl, and pyrimidine-4-yl, each of which is optionally substituted with one or two groups independently chosen from alkynyl, cyano, optionally substituted amino, halo, lower alkyl, and lower alkyl substituted with optionally substituted amino.

[0099] In some embodiments, R.sub.1 is chosen from 5-cyano-pyrimidine-4-yl, pyridine-4-yl, 5-bromo-1,2-dihydropyridin-2-one-3-yl, 3-acetamido-pyridine-4-yl, 2-acetamido-pyridine-6-yl, 3-cyano-pyridine-4-yl, 3-cyano-pyridine-6-yl, 3-bromo-pyridine-4-yl, 3-bromo-pyridine-2-yl, 3-cyano-pyridine-2-yl, 3-fluoro-pyridine-4-yl, 2-cyano-pyridine-4-yl, 4-cyano-pyridine-3-yl, and 3-ethynyl-pyridine-4-yl.

[0100] In some embodiments, R.sub.1 is pyridine-4-yl or 3-cyano-pyridine-4-yl.

[0101] In some embodiments, R.sub.1 is heterocycloalkenyl optionally substituted with lower alkyl.

[0102] In some embodiments, R.sub.1 is 2,3-dihydropyridazine-6-yl optionally substituted with lower alkyl.

[0103] In some embodiments, L.sub.1 is O.

[0104] In some embodiments, m is 1.

[0105] In some embodiments, R.sub.2 is chosen from hydrogen, aryl, aryl substituted with hydroxyl or lower alkoxy, heteroaryl, and heteroaryl substituted with hydroxyl or lower alkoxy.

[0106] In some embodiments, R.sub.2 is chosen from hydrogen, heteroaryl, and heteroaryl substituted with hydroxyl or lower alkoxy.

[0107] In some embodiments, R.sub.2 is chosen from hydrogen, phenyl, pyridine-2-yl, pyrimidine-5-yl, pyrazin-2-yl, and pyrimidin-5-yl, each of which, other than hydrogen, is optionally substituted with hydroxyl or lower alkoxy.

[0108] In some embodiments, R.sub.2 is chosen from hydrogen, pyridine-2-yl, pyrimidine-5-yl, pyrazin-2-yl, and pyrimidin-5-yl, each of which, other than hydrogen, is optionally substituted with hydroxyl or lower alkoxy.

[0109] In some embodiments, Z.sub.1, Z.sub.2, Z.sub.3, and Z.sub.4 are CH.

[0110] In some embodiments, Z.sub.1 is N and Z.sub.2, Z.sub.3, and Z.sub.4 are CH.

[0111] In some embodiments, Z.sub.2 is N and Z.sub.1, Z.sub.3, and Z.sub.4 are CH.

[0112] In some embodiments, Z.sub.2 and Z.sub.4 are N and Z.sub.1 and Z.sub.3 are CH.

[0113] Also provided is an imaging agent comprising a compound of Formula I is chosen from [0114] 2-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile; [0115] 2-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; [0116] 2-[5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile; [0117] 4-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; [0118] 4-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyrimidine-5-carbonitrile; [0119] 4-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyrimidine-5-carbonitrile; [0120] 4-{5-[(5-hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; [0121] 4-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile; and [0122] 4-[5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile;

[0123] or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or a pharmaceutically acceptable salt there of, is labeled with one or more positron-emitting radionuclides.

[0124] Also provided is an imaging agent comprising a compound of Formula I is chosen from [0125] 2-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile; [0126] 2-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; [0127] 2-[5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile; [0128] 4-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; [0129] 4-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyrimidine-5-carbonitrile; [0130] 4-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyrimidine-5-carbonitrile; [0131] 4-{5-[(5-hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile; [0132] 4-(5-methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile; [0133] 4-[5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile; [0134] 5-[(5-methoxypyrazine-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindole; [0135] 4-[5-(benzyloxy)-2,3-dihydro-1H-isoindol-2-yl]pyrimidine-5-carbonitrile; [0136] 4-{5-[(5-hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyrimidine-5-carbonitrile; [0137] 6-{5-[(5-methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}-2-methyl-2,3-dihydropyridazin-3-one; and [0138] 5-[(5-methoxypyridin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one,
or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or a pharmaceutically acceptable salt there of, is labeled with one or more positron-emitting radionuclides.

[0139] The compounds of Formula I, or a pharmaceutically acceptable salt thereof are labeled with one or more positron-emitting radionuclides. Suitable positron-emitting radionuclides that may be incorporated in the compounds of described herein, but are not limited to, .sup.11C, .sup.13N, .sup.15O, .sup.18F, .sup.52Fe, .sup.62Cu, .sup.64Cu, .sup.68Ga, .sup.74As, .sup.82Rb, .sup.89Zr, .sup.122I, and .sup.124I. In some embodiments, the one or more positron-emitting radionuclides are selected from: .sup.11C, .sup.13N, .sup.15O, .sup.18F, .sup.76Br, and .sup.124I. In some embodiments the one or more positron-emitting radionuclides are selected from .sup.11C, .sup.13N, .sup.15O, and .sup.18F.

[0140] Non-metal radionuclides may be covalently linked to the compounds described herein by a reaction well known from the state of art. When the radionuclide is a metallic positron-emitter, it is understood that labeling may require the use of a chelating agent. Such chelating agents are well known from the state of the art.

[0141] A PET imaging agent may be labelled with the positron emitter .sup.11C or .sup.18F. Methods for the introduction of .sup.11C may include, but are not limited to, alkylation with [.sup.11C]iodomethane or [.sup.11C]methyl triflate. Carbon-11 has a half-life of approximately 20 minutes, thus .sup.11C needs to be generated in an on-site cyclotron, and is generally produced as [.sup.11C]carbon dioxide. The [.sup.11C]carbon dioxide is converted to the chemical species appropriate for the radiosynthesis (generally [.sup.11C]iodomethane or the like), and the synthesis of the radiopharmaceutical is completed and used on-site in a PET imaging study after the appropriate radiochemical purity and specific activity have been determined. Typical methods of introducing .sup.18F may include but are not limited to displacement of a halide, tosylate, or other leaving group with [.sup.18F]tetrabutylamonium fluoride or [.sup.18F]potassium fluoride kryptofix-222. Fluorine-18 has a half life of approximately 110 minutes, thus synthesis of [.sup.18F]radiopharmaceuticals need not necessarily have to occur at the site of the cyclotron nor proximal to the PET imaging study center. General methods for the introduction of these positron emitters are described in the literature (Miller et al., Angewandte Chemie International Edition, 47 (2008), 8998-9033).

[0142] Provided are methods of generating diagnostic images in an individual comprising administering an effective amount of an imaging agent described herein to an individual, and generating an image of at least a part of the individual.

[0143] Also provided are methods of generating diagnostic images in a biological sample comprising contacting the biological sample with an effective amount of an imaging agent described herein and generating an image of the positron-emitter labeled compound associated with the biological sample. In this method both the contacting and the generating may be conducted in vitro, alternatively the contacting is in vivo and the generating in vitro.

[0144] Also provided are methods for detecting the presence or absence of a neurodegenerative pathologic process associated with huntingtin protein (HTT protein) in an individual comprising: administering an effective amount of a positron-emitter labeled compound described herein; generating an image to detect the presence or absence of HTT protein aggregates in the brain of the individual; and detecting the presence or absence of the pathologic process. In some embodiments, the HTT protein aggregates are present in the basal ganglia of the brain of the individual. In some embodiments, the pathologic process is Huntington's disease (HD). In some embodiments, the effective amount of the imaging agent comprises from about 0.1 to about 20 mCi. In some embodiments, the effective amount of the imaging agent comprises about 10 mCi. In some embodiments, generating an image comprises positron emission tomography (PET) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI), or a combination thereof. In some embodiments, generating an image comprises PET imaging.

[0145] Also provided are diagnostic methods of using the imaging agents to monitor disease progression in a patient by quantifying the change in levels of the target aggregates in the patient.

[0146] Also provided are methods for detecting the presence or absence of a neurodegenerative pathologic process associated with huntingtin protein (HTT protein) in an individual comprising: administering an effective amount of a positron-emitter labeled compound described herein; generating an image to detect the presence or absence of HTT protein aggregates in the individual; and detecting the presence or absence of the pathologic process. In some embodiments, the HTT protein monomers or aggregates are present in the brain, liver, heart, or muscle of said individual. In some embodiments, the HTT protein aggregates are present in the basal ganglia, cortex, hippocampus, or brain stem of the brain of the individual. In some embodiments, the pathologic process is Huntington's disease (HD). In some embodiments, the effective amount of the imaging agent comprises from about 0.1 to about 20 mCi. In some embodiments, the effective amount of the imaging agent comprises about 10 mCi. In some embodiments, generating an image comprises positron emission tomography (PET) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI), or a combination thereof. In some embodiments, generating an image comprises PET imaging.

[0147] Also provided are methods for detecting the presence or absence of a neurodegenerative pathologic process associated with β-amyloid protein in an individual comprising: administering an effective amount of a positron-emitter labeled compound described herein; generating an image to detect the presence or absence of β-amyloid protein aggregates in the individual; and detecting the presence or absence of the pathologic process. In some embodiments, the β-amyloid protein monomers or aggregates are present in the brain, liver, heart, or muscle of said individual. In some embodiments, the β-amyloid protein aggregates are present in the basal ganglia, cortex, hippocampus, or brain stem of the brain of the individual. In some embodiments, the pathologic process is Alzheimer's Disease (AD). In some embodiments, the effective amount of the imaging agent comprises from about 0.1 to about 20 mCi. In some embodiments, the effective amount of the imaging agent comprises about 10 mCi. In some embodiments, generating an image comprises positron emission tomography (PET) imaging, PET with concurrent computed tomography imaging (PET/CT), PET with concurrent magnetic resonance imaging (PET/MRI), or a combination thereof. In some embodiments, generating an image comprises PET imaging.

[0148] Provided herein are compounds having suitable HTT protein aggregate or β-amyloid protein aggregate binding kinetics to function as efficient imaging agents for HTT protein aggregates or β-amyloid protein aggregates. The requirements of the compounds of the invention to function as efficient imaging agents for HTT protein aggregates are: 1) a high affinity for HTT protein aggregates; 2) a low affinity for nearby structures; 3) slow dissociation kinetics from HTT protein aggregates, which may conveniently be expressed as the dissociation rate constant k.sub.diss as defined in the following equation, wherein A and B refer to the HTT protein aggregate and the imaging agent, and k.sub.assn is the association rate constant.

d[AB]/dt=k.sub.assn[A][B]−k.sub.diss[AB]

[0149] The part of the brain most affected by HD, and thus most likely to contain HTT protein abnormalities, is a group of nerve cells at the base of the brain known collectively as the basal ganglia. The basal ganglia organize muscle-driven movements of the body, or “motor movement.” The major components of the basal ganglia are the caudate and the putamen (together known as the striatum) and the globus pallidus (external and internal regions). The substantia nigra and the subthalamic nucleus are often included as part of the basal ganglia as well.

[0150] The term basal ganglia, refers to a group of subcortical nuclei responsible primarily for motor control, as well as other roles such as motor learning, executive functions and behaviors, and emotions. Disruption of the basal ganglia network forms the basis for several movement disorders. Normal function of the basal ganglia requires fine tuning of neuronal excitability within each nucleus to determine the exact degree of movement facilitation or inhibition at any given moment. This is mediated by the complex organization of the striatum, where the excitability of medium spiny neurons is controlled by several pre- and postsynaptic mechanisms as well as interneuron activity, and secured by several recurrent or internal basal ganglia circuits. The motor circuit of the basal ganglia has two entry points, the striatum and the subthalamic nucleus, and an output, the globus pallidus pars interna, which connects to the cortex via the motor thalamus.

[0151] Provided are methods for imaging part of the brain of an individual involving administering a positron-emitter labeled compound described herein to the individual, e.g. into the individual's vascular system, from where it passes through the blood-brain barrier, and then generating an image of at least the part of the individual's brain to which the compound has distributed.

[0152] Also provided are pharmaceutical compositions comprising an effective amount of a positron-emitter labeled compound described herein, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically-acceptable adjuvants, excipients or diluents.

[0153] An imaging agent or pharmaceutical composition thereof may be administered to a patient in need of treatment via any suitable route. Routes of administration may include, for example, parenteral administration (including subcutaneous, intramuscular, intravenous, by means of, for example a drip patch). Further suitable routes of administration include (but are not limited to) oral, rectal, nasal, topical (including buccal and sublingual), infusion, vaginal, intradermal, intraperitoneally, intracranially, intrathecal and epidural administration or administration via oral or nasal inhalation, by means of, for example a nebulizer or inhaler, or by an implant.

[0154] An imaging agent or pharmaceutical composition thereof may also be administered via microspheres, liposomes, other microparticulate delivery systems or sustained release formulations placed in certain tissues including blood. Suitable examples of sustained release carriers include semi-permeable polymer matrices in the form of shared articles, e.g., suppositories or microcapsules. Examples of the techniques and protocols mentioned above and other techniques and protocols which may be used in accordance with the invention can be found in Remington's Pharmaceutical Sciences, 18th edition, Gennaro, A. R., Lippincott Williams & Wilkins; 20th edition (Dec. 15, 2000) ISBN 0-912734-04-3 and Pharmaceutical Dosage Forms and Drug Delivery Systems; Ansel, N. C. et al. 7th Edition ISBN 0-683305-72-7, the entire disclosures of which are herein incorporated by reference.

[0155] Also provided are uses of positron-emitter labeled compounds described herein for the manufacture of an imaging agent for use in a method of diagnosis of an individual.

[0156] Provided are methods of generating diagnostic images comprising proton emission tomography (PET). PET involves the administration of a positron-emitting radionuclide tracer to an individual. Once the tracer has had sufficient time to associate with the target of interest, the individual is placed within in a scanning device comprising a ring of scintillation detectors. An emitted positron travels through the individual's tissue for a short (isotope-dependent) distance, until it interacts with an electron. The interaction annihilates both the electron and the positron, producing a pair of photons moving in approximately opposite directions. These are detected when they reach a scintillator in the scanning device. Photons that do not arrive in pairs are ignored.

[0157] Also provided are methods of generating diagnostic images comprising PET with concurrent computed tomography imaging (PET/CT), or with concurrent magnetic resonance imaging (PET/MRI). Computed tomography uses X-rays to show the structure of the brain, while magnetic resonance imaging uses magnetic fields and radio waves.

[0158] Other uses of the disclosed imaging agents and methods will become apparent to those skilled in the art based upon, inter alia, a review of this disclosure.

[0159] As will be recognized, the steps of the methods described herein need not be performed any particular number of times or in any particular sequence. Additional objects, advantages and novel features of the disclosure will become apparent to those skilled in the art upon examination of the following examples thereof, which are intended to be illustrative and not intended to be limiting.

EXAMPLES

General Experimental Details

[0160] Commercially available reagents and solvents (HPLC grade) were used without further purification. .sup.1H NMR spectra were recorded on a Bruker DRX 500 MHz spectrometer or a Bruker DPX 250 MHz spectrometer in deuterated solvents. Chemical shifts (δ) are in parts per million. SCX chromatography was performed with Biotage Isolute Flash SCX-2 loading the sample in methanol and eluting with methanol then 5% ammonia in methanol.

[0161] Analytical HPLC-MS (METCR1278), was performed on Shimadzu LCMS-2010EV systems using reverse phase Atlantis dC18 columns (3 μm, 2.1×50 mm), gradient 5-100% B (A=water/0.1% formic acid, B=acetonitrile/0.1% formic acid) over 3 minutes injection volume 3 μL, flow=1.0 mL/minute. UV spectra were recorded at 215 nm using a SPD-M20A photo diode array detector. Mass spectra were obtained over the range m/z 150 to 850 at a sampling rate of 2 scans per second using a LCMS2010EV. Data were integrated and reported using Shimadzu LCMS-Solutions and PsiPort software.

[0162] Alternatively, (METCR1416) analytical HPLC-MS on Shimadzu LCMS-2010EV systems using reverse phase Water Atlantis dC18 columns (3 μm, 2.1×100 mm), gradient 5-100% B (A=water/0.1% formic acid, B=acetonitrile/0.1% formic acid) over 7 minutes, injection volume 3 μL, flow=0.6 mL/minute. UV spectra were recorded at 215 nm using a SPD-M20A photo diode array detector. Mass spectra were obtained over the range m/z 150 to 850 at a sampling rate of 2 scans per second using a LCMS2010EV. Data were integrated and reported using Shimadzu LCMS-Solutions and PsiPort software.

[0163] Alternatively, (MET-uHPLC-AB-101) analytical HPLC-MS were performed on a Waters Acquity UPLC system with Waters PDA and ELS detectors using a Phenomenex Kinetex-XB C-18 column, (1.7 μM, 2.1 mm×100 mm at a column temperature of 40° C., gradient 5-100% B (A=water/0.1% formic acid; B=acetonitrile/0.1% formic acid) over 5.3 minutes, then 100% B for 0.5 minute, flow=0.6 mL/minute. UV spectra were recorded at 215 nm using a Waters Acquity photo diode array. Mass spectra were obtained over the range m/z 150 to 850 at a sampling rate of 5 scans per second using a Waters SQD. Data were integrated and reported using Waters MassLynx and OpenLynx software.

[0164] All example compounds display an LC purity of >95% unless stated otherwise.

Method 1

[0165] ##STR00005##

Step 1, Method 1: 5-(Chloromethyl)pyrimidine Hydrochloride

[0166] To a solution of pyrimidin-5-ylmethanol (48 mg, 0.43 mmol) in dichloromethane (3 mL), thionyl dichloride (0.26 mL, 3.6 mmol) was added drop-wise at 0° C. The mixture was heated to reflux for 2 hours, then the mixture was concentrated. Dichloromethane (5 mL) was added and the mixture was concentrated (×3) to give the title compound as a yellow oil which was used directly in the next step. Tr(METCR1278)=0.90 min, (ES.sup.+) (M+H).sup.+ 129/131.

Step 2, Method 1: 4-(5-Methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile

[0167] 5-Methoxy-2,3-dihydro-1H-isoindole hydrochloride (500 mg, 2.69 mmol), 4-chloropyridine-3-carbonitrile (448 mg, 3.23 mmol) and diisopropylethylamine (1.4 mL, 8.08 mmol) were suspended in n-butanol (6 mL). The reaction was heated in a microwave at 140° C. for 1 hour. The reaction mixture was partitioned between ethyl acetate (50 mL) and water (30 mL) and the aqueous was extracted with ethyl acetate (2×30 mL). The combined organic extracts were washed with brine (15 mL), dried over anhydrous sodium sulphate, filtered and concentrated. Purification by FCC (silica, 20-100% ethyl acetate in heptane) gave the title compound 230 mg (34% yield) as an off white solid. Tr(METCR1278)=1.28 min, (ES.sup.+) (M+H).sup.+ 252.

Step 3, Method 1: 4-(5-Hydroxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile

[0168] 4-(5-Methoxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile (230 mg, 0.92 mmol) was dissolved in dichloromethane (15 mL) and stirred in a nitrogen atmosphere. The reaction mixture was cooled to 0° C. and 1 M boron tribromide in dichloromethane (4.58 mL, 4.58 mmol) was added slowly. The reaction mixture was allowed to warm to room temperature and was stirred for 48 hours. The reaction mixture was cooled to 0° C. and methanol (20 mL) was added slowly. The solvents were removed in vacuo to give the title compound 313 mg (quantitative yield) as a beige solid. Tr(METCR1278)=1.36 min, (ES.sup.+) (M+H).sup.+ 238, 90%.

Step 4, Method 1: 4-[5-(Pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile

[0169] 4-(5-Hydroxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile (90%, 313 mg, 1.19 mmol), 5-(chloromethyl)pyrimidine hydrochloride (crude 1.42 mmol) and potassium iodide (217 mg, 1.31 mmol) were dissolved in anhydrous N,N-dimethylformamide (3 mL) and stirred for 5 minutes at room temperature. Sodium hydride (60% in mineral oil, 142 mg, 3.56 mmol) was added and the reaction mixture was stirred at room temperature for 24 hours. Water (0.1 mL) was added and the solvents were removed in vacuo. The residue was partitioned between ethyl acetate (50 mL) and water (50 mL) and the aqueous phase was extracted with ethyl acetate (2×50 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulphate, filtered and concentrated. Purification by preparative HPLC (acetonitrile-water-0.2% ammonium hydroxide) gave the title compound 19.5 mg (5% yield) as an off white solid.

Example 1, Method 1: 4-[5-(Pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-isoindol-2-yl]pyridine-3-carbonitrile

[0170] δ.sub.H NMR (500 MHz, DMSO) 9.19 (s, 1H), 8.93 (s, 2H), 8.51 (s, 1H), 8.29 (d, J=6.3 Hz, 1H), 7.37 (d, J=8.4 Hz, 1H), 7.16 (d, J=1.9 Hz, 1H), 7.05 (dd, J=8.4, 2.3 Hz, 1H), 6.77 (d, J=6.3 Hz, 1H), 5.23 (s, 2H), 5.03 (s, 2H), 4.97 (s, 2H). Tr(MET-uHPLC-AB-101)=1.4 min, (ES.sup.+) (M+H).sup.+ 330.

[0171] The following examples were prepared using Method 1 described above:

TABLE-US-00001 TABLE 1 Mol. Ex. Structure Weight IUPAC Name LCMS data 1 [00006] 329.36 4-[5-(Pyrimidin-5- ylmethoxy)-2,3- dihydro-1H- isoindol-2- yl]pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101) = 1.4 min, (ES.sup.+) (M + H).sup.+ 330 2 [00007] 251.28 2-(5-Methoxy-2,3- dihydro-1H- isoindol-2- yl)pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101) = 3.42 min, (ES.sup.+) (M + H).sup.+ 252 3 [00008] 358.39 2-{5-[(5- Methoxypyridin-2- yl)methoxy]-2,3- dihydro-1H- isoindol-2- yl}pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101) = 3.32 min, (ES.sup.+) (M + H).sup.+ 359 4 [00009] 329.36 2-[5-(Pyrimidin-5- ylmethoxy)-2,3- dihydro-1H- isoindol-2- yl]pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101) = 3.0 min, (ES.sup.+) (M + H).sup.+ 330 5 [00010] 358.39 4-{5-[(5- Methoxypyridin-2- yl)methoxy]-2,3- dihydro-1H- isoindol-2- yl}pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101)= 1.7 min, (ES.sup.+) (M + H).sup.+ 359 6 [00011] 252.27 4-(5-Methoxy-2,3- dihydro-1H- isoindol-2- yl)pyrimidine-5- carbonitrile Tr(METCR1416) = 2.75 min, (ES.sup.+) (M + H).sup.+ 253 7 [00012] 359.38 4-{5-[(5- Methoxypyridin-2- yl)methoxy]-2,3- dihydro-1H- isoindol-2- yl}pyrimidine-5- carbonitrile Tr(MET-uHPLC- AB-101) = 2.76 min, (ES.sup.+) (M + H).sup.+ 360 8 [00013] 251.28 4-(5-Methoxy-2,3- dihydro-1H- isoindol-2- yl)pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101) = 1.47 min, (ES.sup.+) (M + H).sup.+ 252 9 [00014] 328.38 4-[5-(Benzyloxy)- 2,3-dihydro-1H- isoindol-2- yl]pyrimidine-5- carbonitrile Tr(MET-uHPLC- AB-101) = 3.68 min, (ES.sup.+) (M + H).sup.+ 329

Method 2

[0172] ##STR00015##

Step 1, Method 2: Methyl 5-(methoxymethoxy)pyridine-2-carboxylate

[0173] Sodium hydride (60% in mineral oil, 144 mg, 3.59 mmol) was suspended in anhydrous N,N-dimethyl formamide (5 mL) and cooled to 0° C. Methyl 5-hydroxypyridine-2-carboxylate (500 mg, 3.27 mmol) dissolved in N,N-dimethylformamide (5 mL) was added slowly to the suspension. The reaction mixture was allowed to stir under nitrogen and warm to room temperature over 30 minutes. The reaction was cooled to 0° C. and chloro(methoxy)methane (0.26 mL, 3.43 mmol) was added drop-wise over 15 minutes. The reaction was allowed to warm to room temperature and stirred for 16 hours. Water (20 mL) was added and the solvents were removed in vacuo. The mixture was partitioned between ethyl acetate and water (1:1, 100 mL) and extracted with ethyl acetate (3×60 mL). The combined organic extracts were washed with water (3×80 mL), brine (50 mL), dried over anhydrous magnesium sulphate, filtered and concentrated to give the title compound 0.6 g (89% yield) as an orange oil which solidified upon standing. Tr(METCR1278)=1.33 min, (ES.sup.+) (M+H).sup.+ 198.

Step 2, Method 2: [5-(Methoxymethoxy)pyridin-2-yl]methanol

[0174] Methyl 5-(methoxymethoxy)pyridine-2-carboxylate (0.39 g, 1.9 mmol) was dissolved in anhydrous tetrahydrofuran (15 mL) and cooled to 0° C. in a nitrogen atmosphere. 2.4 M lithium aluminium hydride in tetrahydrofuran (0.87 mL, 2.09 mmol) was added drop-wise over a period of 5 minutes, and the reaction was stirred at 0° C. for 1.5 hours. The reaction was cooled to 0° C. and saturated aqueous Rochelle's salt (1 mL) was added drop-wise with vigorous stirring over a period of 10 minutes. The reaction mixture was allowed to warm to room temperature for 1 hour. The resultant emulsion was filtered through glass fibre filter paper. The filter paper was washed with saturated aqueous sodium bicarbonate (10 mL), followed by ethyl acetate (3×10 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (3×10 mL). The combined organic extracts were washed with brine (10 mL), dried over anhydrous sodium sulphate, filtered, and concentrated to give the title compound 276 mg (86% yield) as an orange oil. Tr(METCR1278)=1.09 min, (ES.sup.+) (M+H).sup.+ 170.

Step 3, Method 2: [5-(Methoxymethoxy)pyridin-2-yl]methyl methanesulfonate

[0175] [5-(Methoxymethoxy)pyridin-2-yl]methanol (276 mg, 1.63 mmol) was dissolved in dichloromethane (5 mL), cooled to 0° C. and stirred in a nitrogen atmosphere. Triethylamine (250 μL, 1.79 mmol) was added, followed by drop-wise addition of methanesulfonyl chloride (133 μL, 1.71 mmol). The reaction was stirred for 45 minutes at 0° C. and allowed to warm to room temperature. Water (5 mL) was added and the phases separated. The aqueous layer was extracted with dichloromethane (3×15 mL); the combined organic extracts were washed with brine (10 mL), dried over anhydrous sodium sulphate, filtered, and concentrated to give the title compound, 275 mg (59% yield) as a dark red oil. Tr(METCR1278)=1.35 min, (ES.sup.+) (M+H).sup.+ 248.

Step 4, Method 2: 4-(5-{[5-(Methoxymethoxy)pyridin-2-yl]methoxy}-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile

[0176] 4-(5-Hydroxy-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile (330 mg, 1.66 mmol prepared by Method 1), [5-(methoxymethoxy)pyridin-2-yl]methyl methanesulfonate (532 mg, 1.66 mmol) and potassium iodide (62 mg, 0.37 mmol) were dissolved in anhydrous N,N-dimethylformamide (4 mL). Sodium hydride (60% in mineral oil, 27 mg, 0.16 mmol) was added and the mixture was stirred at room temperature for 44 hours. The reaction mixture was quenched with methanol (2 mL) and partitioned between ethyl acetate (100 mL), saturated aqueous sodium bicarbonate (50 mL) and brine (50 mL). After separation the aqueous layer was extracted with ethyl acetate (3×100 mL). The organic extracts were combined, washed with brine (30 mL), dried over sodium sulphate and concentrated. The residue was triturated with ethyl acetate:heptane (1:1) to give the title compound 269 mg (39% yield) as a brown solid. δH NMR (500 MHz, DMSO) 8.49 (s, 1H), 8.33 (d, J=2.6 Hz, 1H), 8.27 (d, J=6.3 Hz, 1H), 7.49 (d, J=2.7 Hz, 1H), 7.48 (s, 1H), 7.32 (d, J=8.4 Hz, 1H), 7.09 (d, J=1.9 Hz, 1H), 6.98 (dd, J=8.4, 2.3 Hz, 1H), 6.74 (d, J=6.3 Hz, 1H), 5.26 (s, 2H), 5.12 (s, 2H), 4.96 (d, J=22.4 Hz, 4H), 3.38 (s, 3H).

Step 5, Method 2: 4-{5-[(5-Hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile

[0177] To a solution of 4-(5-{[5-(methoxymethoxy)pyridin-2-yl]methoxy}-2,3-dihydro-1H-isoindol-2-yl)pyridine-3-carbonitrile (269 mg, 0.69 mmol) in tetrahydrofuran (40 mL) was added 3 M hydrochloric acid (4.6 mL) and the mixture was stirred at 60° C. for 8 hours. The mixture was stirred overnight at room temperature. The volatiles were removed in vacuo and the remaining residue was diluted with water. Solid sodium bicarbonate was added portion-wise until the pH was approximately 8. The solid was collected by filtration, washed with water (2×10 mL) and dried under vacuum. Purification by FCC (silica, 0-60% tetrahydrofuran in heptane) gave the title compound 101 mg (42% yield) as a white solid.

Example 4, Method 2: 4-{5-[(5-Hydroxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}pyridine-3-carbonitrile

[0178] δ.sub.H NMR (500 MHz, DMSO) 10.01 (s, 1H), 8.49 (s, 1H), 8.27 (d, J=6.3 Hz, 1H), 8.11 (d, J=2.5 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.32 (d, J=8.4 Hz, 1H), 7.18 (dd, J=8.4, 2.9 Hz, 1H), 7.08 (d, J=2.0 Hz, 1H), 6.97 (dd, J=8.4, 2.4 Hz, 1H), 6.75 (d, J=6.3 Hz, 1H), 5.05 (s, 2H), 4.98 (s, 2H), 4.94 (s, 2H). Tr(MET-uHPLC-AB-101)=1.28 min, (ES.sup.+) (M+H).sup.+ 345.

[0179] The following examples were prepared using Method 2 described above:

TABLE-US-00002 TABLE 2 Mol. Ex. Structure Weight IUPAC Name LCMS data 1 [00016] 344.37 4-{5-[(5- Hydroxypyridin-2- yl)methoxy]-2,3- dihydro-1H- isoindol-2- yl}pyridine-3- carbonitrile Tr(MET-uHPLC- AB-101) = 1.28 min, (ES.sup.+) (M + H).sup.+ 345 2 [00017] 345.36 4-{5-[(5- Hydroxypyridin-2- yl)methoxy]-2,3- dihydro-1H- isoindol-2- yl}pyrimidine-5- carbonitrile Tr(MET-uHPLC- AB-101) = 2.02 min, (ES.sup.+) (M + H).sup.+ 346

Method 3

[0180] ##STR00018##

Step 1, Method 3: Methyl 5-methoxypyrazine-2-carboxylate

[0181] To methyl 5-chloropyrazine-2-carboxylate (2.00 g, 11.6 mmol) under nitrogen, was added a 0.5 M solution of sodium methoxide in methanol (27.8 mL, 13.9 mmol). The mixture was refluxed at 90° C. for 15 minutes. The mixture was then dissolved with water (80 mL) and extracted with ethyl acetate (2×100 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated to give the title compound 1.68 g (79% yield) as a white powder. δ.sub.H NMR (500 MHz, Chloroform) 8.88 (d, J=1.2 Hz, 1H), 8.28 (d, J=1.2 Hz, 1H), 4.05 (s, 3H), 4.00 (s, 3H). Tr(METCR1278)=1.23 min, (ES.sup.+) (M+H).sup.+ 169.

Step 2, Method 3: (5-Methoxypyrazin-2-yl)methanol

[0182] Sodium borohydride (270 mg, 7.14 mmol) was added to a stirred solution of methyl 5-methoxypyrazine-2-carboxylate (200 mg, 1.19 mmol) in anhydrous tetrahydrofuran (8 mL) under nitrogen. The mixture was refluxed at 65° C. for 15 minutes, after which methanol (1.59 mL, 39.2 mmol) was added slowly. The reaction was refluxed at 65° C. for 1.5 hours. The mixture was quenched with water (0.5 mL), then diluted with further water (15 mL), extracted with ethyl acetate (2×25 mL) then 20% 2-propanol in dichloromethane (25 mL). The combined organic extracts were dried over sodium sulphate, filtered and concentrated to give the title compound 115 mg (69% yield) as a white crystalline solid. δ.sub.H NMR (500 MHz, DMSO) 8.28-8.16 (m, 2H), 5.41 (t, J=5.8 Hz, 1H), 4.54 (d, J=5.6 Hz, 2H), 3.90 (s, 3H). Tr(METCR1278)=0.74 min, (ES.sup.+) (M+H).sup.+ 141.

Step 3, Method 3: (5-Methoxypyrazin-2-yl)methyl methanesulfonate

[0183] To a stirred solution of (5-methoxypyrazin-2-yl)methanol (73 mg, 0.52 mmol) in dichloromethane (1 mL) under nitrogen, was added triethylamine (0.08 mL, 0.73 mmol) followed by methanesulfonyl chloride (0.042 mL, 0.55 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was then partitioned between dichloromethane (10 mL) and water (10 mL). The organic extract was dried over sodium sulphate, filtered and concentrated to afford the title compound 59 mg (52% yield) as a yellow oil. Tr(METCR1278)=1.25 min, (ES.sup.+) (M+H).sup.+ 219.

Step 4, Method 3: 5-[(5-Methoxypyrazin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindole

[0184] 2-(Pyridin-4-yl)-2,3-dihydro-1H-isoindol-5-ol (87%, 289 mg, 1.18 mmol, prepared by Method 1), (5-methoxypyrazin-2-yl)methyl methanesulfonate (310 mg, 1.42 mmol) and potassium iodide (197 mg, 1.18 mmol) were dissolved in anhydrous N,N-dimethyl formamide (5 mL) and stirred for 5 minutes at room temperature. Sodium hydride (60% in mineral oil, 142 mg, 3.55 mmol) was added and the reaction mixture was stirred at room temperature under a nitrogen atmosphere for 40 hours. The solvents were removed in vacuo and purification by preparative HPLC (acetonitrile-water-0.2% ammonium hydroxide) gave the title compound, 30.1 mg (8% yield) as a beige solid.

Example 1, Method 3: 5-[(5-Methoxypyrazin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindole

[0185] δ.sub.H NMR (500 MHz, DMSO) 8.38 (d, J=1.1 Hz, 1H), 8.34 (d, J=1.3 Hz, 1H), 8.17 (d, J=6.3 Hz, 2H), 7.32 (d, J=8.3 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.01 (dd, J=8.4, 2.3 Hz, 1H), 6.57 (d, J=6.4 Hz, 2H), 5.17 (s, 2H), 4.62 (s, 2H), 4.58 (s, 2H), 3.92 (s, 3H). Tr(MET-uHPLC-AB-101)=1.77 min, (ES.sup.+) (M+H).sup.+ 335.

[0186] The following example was prepared using Method 3 described above:

TABLE-US-00003 TABLE 3 Mol. Ex. Structure Weight IUPAC Name LCMS data 1 [00019] 334.37 5-[(5- Methoxypyrazin-2- yl)methoxy]-2- (pyridin-4-yl)-2,3- dihydro-1H- isoindole Tr(MET-uHPLC- AB-101) = 1.77 min, m/z (ES.sup.+) (M + H).sup.+ 335

Method 4

[0187] ##STR00020##

Step 1, Method 4: 6-(5-Methoxy-2,3-dihydro-1H-isoindol-2-yl)-2-methyl-2,3-dihydropyridazin-3-one

[0188] 5-Methoxy-2,3-dihydro-1H-isoindole hydrochloride (170 mg, 0.92 mmol), 6-bromo-2-methyl-2,3-dihydropyridazin-3-one (182 mg, 0.96 mmol) and dicaesium carbonate (895.06 mg, 2.75 mmol) were suspended in anhydrous toluene (3 mL) and sonicated under a flow of nitrogen for 5 minutes. Palladium(II) acetate (20.56 mg, 0.09 mmol) and 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (53 mg, 0.09 mmol) were added and the reaction was heated to 100° C. for 16 hours. The reaction mixture was cooled to room temperature and filtered through celite. The celite was washed with 10% methanol in dichloromethane and the filtrate was concentrated in vacuo and purified by FCC (silica, 20-100% ethyl acetate in heptane, 0-10% methanol in dichloromethane), SCX and HPLC (acetonitrile/water +0.2% formic acid) to give the title compound, 34 mg (14% yield) as a beige solid. δ.sub.H NMR (500 MHz, DMSO) 7.30 (d, J=9.8 Hz, 1H), 7.27 (d, J=8.3 Hz, 1H), 6.96 (d, J=2.0 Hz, 1H), 6.92-6.84 (m, 2H), 4.63 (s, 2H), 4.59 (s, 2H), 3.76 (s, 3H), 3.53 (s, 3H). Tr(MET-uHPLC-AB-101)=2.56 min, (ES.sup.+) (M+H).sup.+ 258.

Step 2, Method 4: 6-(5-Hydroxy-2,3-dihydro-1H-isoindol-2-yl)-2-methyl-2,3-dihydropyridazin-3-one

[0189] 6-(5-Methoxy-2,3-dihydro-1H-isoindol-2-yl)-2-methyl-2,3-dihydropyridazin-3-one (96 mg, 0.37 mmol) was dissolved in anhydrous dichloromethane (5 mL) and 1 M tribromoborane in dichloromethane (0.6 mL) was added and the reaction was stirred at room temperature for 16 hours. 1 M tribromoborane in dichloromethane (0.2 mL) was added and the reaction was stirred at room temperature for 2 hours. Saturated sodium bicarbonate solution (15 mL) was added and the reaction mixture was stirred vigorously for 20 minutes. The reaction mixture was filtered and the precipitate was co-distilled from methanol (5 mL) and toluene (2×10 mL) to give the title compound, 84 mg (90% yield) as a beige solid. δ.sub.H NMR (500 MHz, DMSO) 7.29 (d, J=9.8 Hz, 1H), 7.14 (d, J=8.2 Hz, 1H), 6.88 (d, J=9.8 Hz, 1H), 6.75 (s, 1H), 6.69 (dd, J=8.2, 2.1 Hz, 1H), 4.58 (s, 2H), 4.55 (s, 2H), 3.52 (s, 3H). Tr(METCR1673)=0.94 min, (ES.sup.+) (M.sup.+H).sup.+ 244.

Step 3, Method 4: 6-{5-[(5-Methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}-2-methyl-2,3-dihydropyridazin-3-one

[0190] (5-Methoxypyridin-2-yl)methanol (54 mg, 0.37 mmol) was dissolved in anhydrous dichloromethane (3 mL), thionyl dichloride (0.25 ml, 3.35 mmol) was added and the reaction was heated to 50° C. in a nitrogen atmosphere for 2 hours. The reaction mixture was cooled to room temperature, concentrated in vacuo from dichloromethane (3×10 mL), to give a brown oil which was used crude in the subsequent step. 6-(5-Hydroxy-2,3-dihydro-1H-isoindol-2-yl)-2-methyl-2,3-dihydropyridazin-3-one (97%, 84 mg, 0.33 mmol), potassium iodide (61 mg, 0.37 mmol) and 2-(chloromethyl)-5-methoxypyridine (58 mg, 0.37 mmol) were dissolved in anhydrous N,N-di methyl Form amide (5 mL), sodium hydride (60%, 40.19 mg, 1 mmol) was added and the reaction was stirred for 1 hour at room temperature in a nitrogen atmosphere. Sodium hydride (60%, 40 mg, 1 mmol) was added and the reaction was heated to 70° C. for 3 hours. The reaction mixture was cooled to room temperature, quenched with the addition of water (1 mL) and the solvents were removed in vacuo and the stood for 16 hours. The residue was partitioned between ethyl acetate (50 mL) and water (50 mL), the phases were separated and the aqueous layer was further extracted with ethyl acetate (2×50 mL), the combined organics were washed with brine (10 mL), dried over anhydrous magnesium sulfate, filtered, and the filtrate was evaporated in vacuo. Purification by FCC (silica, 20-100% ethyl acetate in heptane, 10% methanol in dichloromethane) gave the title compound, 32 mg (26% yield) as a beige solid.

Example 1, Method 4: 6-{5-[(5-Methoxypyridin-2-yl)methoxy]-2,3-dihydro-1H-isoindol-2-yl}-2-methyl-2,3-dihydropyridazin-3-one

[0191] δ.sub.H NMR (500 MHz, DMSO) 8.28 (d, J=2.8 Hz, 1H), 7.47 (d, J=8.6 Hz, 1H), 7.42 (dd, J=8.6, 2.9 Hz, 1H), 7.30 (d, J=9.8 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 7.05 (d, J=2.0 Hz, 1H), 6.95 (dd, J=8.4, 2.3 Hz, 1H), 6.89 (d, J=9.8 Hz, 1H), 5.11 (s, 2H), 4.62 (s, 2H), 4.59 (s, 2H), 3.83 (s, 3H), 3.53 (s, 3H). Tr(MET-uHPLC-AB-101)=2.56 min, (ES.sup.+) (M+H).sup.+ 365.

[0192] The following example was prepared using Method 4 described above:

TABLE-US-00004 TABLE 4 Mol. Ex. Structure Weight IUPAC Name LCMS data 1 [00021] 364.41 6-{5-[(5- Methoxypyridin-2- yl)methoxy]-2,3- dihydro-1H- isoindol-2-yl}-2- methyl-2,3- dihydropyridazin- 3-one Tr(MET-uHPLC- AB-101) = 2.56 min, m/z (ES.sup.+) (M + H).sup.+ 365

Method 5

[0193] ##STR00022##

Step 1, Method 5: 5-Methoxy-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one

[0194] 5-Methoxy-2,3-dihydro-1H-isoindol-1-one (100 mg, 0.61 mmol), 4-iodopyridine (126 mg, 0.61 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane) (53 mg, 0.09 mmol) and dicaesium carbonate (300 mg, 0.92 mmol) were suspended in dry dioxane (1 mL) and the mixture was degassed. (1E,4E)-1,5-Diphenylpenta-1,4-dien-3-one-palladium (3:2) (28 mg, 0.03 mmol) was added and the mixture heated in a microwave at 140° C. for 90 minutes. The mixture was diluted with ethyl acetate (10 mL) and water (5 mL) and filtered to give the title compound 28 mg (20% yield) as a brown powder. δ.sub.H NMR (500 MHz, DMSO) 8.58-8.47 (m, 2H), 7.91-7.82 (m, 2H), 7.74 (d, J=8.5 Hz, 1H), 7.23 (d, J=1.9 Hz, 1H), 7.11 (dd, J=8.5, 2.3 Hz, 1H), 4.98 (s, 2H), 3.89 (s, 3H). Tr(MET-uHPLC-AB-101)=1.27 min, (ES.sup.+) (M+H).sup.+ 241.

Step 2, Method 5: 5-Hydroxy-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one

[0195] To 5-methoxy-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one (37 mg, 0.15 mmol in 1,2-dichloroethane (10 mL) was added tribromoborane 1 M in dichloromethane (1.54 mL 1.54 mmol) and the mixture heated to reflux overnight. Tribromoborane 1 M in dichloromethane (1.54 mL 1.54 mmol) and the mixture heated to reflux for 2 days the stood at room temperature for 2 days. The mixture was poured onto a 1:1 ice:saturate sodium bicarbonate mixture (50 mL) and stirred for 1 hour. The mixture was filtered and washed with water (5 mL) and dichloromethane then dried in a vacuum oven to give the title compound 19 mg (55% yield) as a tan powder. δ.sub.H NMR (250 MHz, DMSO, 353 K) 8.72 (d, J=7.4 Hz, 2H), 8.30 (d, J=7.4 Hz, 2H), 7.73 (d, J=8.3 Hz, 1H), 7.01 (dd, J=11.3, 3.0 Hz, 2H), 5.05 (s, 2H). Tr(METCR0990)=0.85 min, (ES.sup.+) (M+H).sup.+ 227.

Step 3, Method 5: 5-[(5-Methoxypyridin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one

[0196] (5-Methoxypyridin-2-yl)methanol (95%, 18 mg, 0.13 mmol) was dissolved in anhydrous dichloromethane (3 mL), thionyl dichloride (61 μl, 0.84 mmol) was added and the reaction was heated to 50° C. under a nitrogen atmosphere for 2 hours. The reaction mixture was cooled to room temperature, concentrated in vacuo to give a brown oil which was used crude in the following step. 5-Hydroxy-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one (19 mg, 0.08 mmol) and 2-(chloromethyl)-5-methoxypyridine (20 mg, 0.13 mmol) were dissolved in anhydrous N,N-dimethylformamide (2 mL), sodium hydride (60%, 40.19 mg, 1 mmol) was added and the reaction was stirred overnight at room temperature under a nitrogen atmosphere. The reaction mixture was quenched with the addition of water (5 mL) and filtered, washed with water (3 mL), heptane (5 mL) and methanol (2 mL) and dried in a vacuum oven to give the title compound 7 mg (24% yield) as a brown powder.

Example 1 Method 5: 5-[(5-Methoxypyridin-2-yl)methoxy]-2-(pyridin-4-yl)-2,3-dihydro-1H-isoindol-1-one

[0197] δ.sub.H NMR (500 MHz, DMSO) 8.56-8.48 (m, 2H), 8.31 (d, J=2.9 Hz, 1H), 7.90-7.85 (m, 2H), 7.74 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.6 Hz, 1H), 7.44 (dd, J=8.6, 2.9 Hz, 1H), 7.31 (d, J=1.6 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 5.24 (s, 2H), 4.97 (s, 2H), 3.84 (s, 3H). Tr(MET-uHPLC-AB-101)=1.59 min, (ES.sup.+) (M+H).sup.+ 348.

[0198] The following example was prepared using Method 5 described above:

TABLE-US-00005 TABLE 5 Mol. Ex. Structure Weight IUPAC Name LCMS data 1 [00023] 347.37 5-[(5- Methoxypyridin-2- yl)methoxy]-2- (pyridin-4-yl)-2,3- dihydro-1H- isoindol-1-one Tr(MET-uHPLC- AB-101) = 1.59 min, m/z (ES.sup.+) (M + H).sup.+ 348

Biology Examples

Q46 Radioligand Binding Assay

[0199] For radioligand binding assays (RBA) GST-Q46 protein was generated based on a previous publication (Scherzinger et al. Cell, Vol. 90, 549-558, Aug. 8, 1997). For experiments 33 μM GST-Q46 was incubated with 150 μg/ml thrombin in assay buffer (150 mM NaCl, 50 mM Tris pH 8.0) and 2 mM CaCl.sub.2 for 16 hr at 37° C. Aggregated Q46 was pelleted by centrifugation for 5 min at 13,000 rpm in a bench top centrifuge and re-dissolved in the same volume of assay buffer. Test compounds were prepared by titration in DMSO at 11 concentrations from 33 μM to 1 nM. For the RBA, Q46 protein aggregates and test compounds were pre-incubated in assay buffer for 20 min at room temperature, in 140 μL/well in a 96-well plate (pp, round bottom). Then, ligand was added in 10 μL/well and incubated for 60 minutes at 37° C. Final assay concentrations were 1 μM to 30 μM test compound, 5 μM Q46 protein (equivalent monomer concentration) and 10 nM ligand [.sup.3H.sub.3]MK-3328 (Harrision et al., ACS Med Chem. Lett., 2 (2011), pp 498-502). Samples were transferred onto GF/B filter plates and washed 2× with 200 μL PBS using a Filtermate Harvester. After drying filter plates for 1 hour at 37° C., the back of the plates was sealed with foil and 30 μL/well scintillation fluid (Packard MicroScint 40) was added, incubated for 15 min in the dark and counted in a TopCount reader. For analysis, replicate data from independent assay plates were normalized towards 0% and 100% inhibition using control wells of vehicle (0% inhibition) and 3 μM unlabelled MK-3328 (100% inhibition). IC.sub.50 values were determined with a sigmoidal inhibition model with four variables (top, bottom, slope, IC.sub.50) in a global fit using the normalized replicate data.

TABLE-US-00006 RBA IC.sub.50 summary: <100 nM +++, 100-500 nM ++, >500 nM + Structure IUPAC Name Activity [00024] 4-(5-methoxy-2,3-dihydro-1H- isoindol-2-yl)pyridine-3- carbonitrile +++ [00025] 5-[(5-methoxypyrazin-2- yl)methoxy]-2-(pyridin-4-yl)-2,3- dihydro-1H-isoindole +++ [00026] 4-[5-(pyrimidin-5-ylmethoxy)-2,3- dihydro-1H-isoindol-2-yl]pyridine- 3-carbonitrile +++ [00027] 2-(5-methoxy-2,3-dihydro-1H- isoindol-2-yl)pyridine-3- carbonitrile +++ [00028] 2-{5-[(5-methoxypyridin-2- yl)methoxy]-2,3-dihydro-1H- isoindol-2-yl}pyridine-3- carbonitrile +++ [00029] 2-[5-(pyrimidin-5-ylmethoxy)-2,3- dihydro-1H-isoindol-2-yl]pyridine- 3-carbonitrile +++ [00030] 4-{5-[(5-methoxypyridin-2- yl)methoxy]-2,3-dihydro-1H- isoindol-2-yl}pyridine-3- carbonitrile +++ [00031] 4-(5-methoxy-2,3-dihydro-1H- isoindol-2-yl)pyrimidine-5- carbonitrile +++ [00032] 4-{5-[(5-methoxypyridin-2- yl)methoxy]-2,3-dihydro-1H- isoindol-2-yl}pyrimidine-5- carbonitrile +++ [00033] 4-{5-[(5-hydroxypyridin-2- yl)methoxy]-2,3-dihydro-1H- isoindol-2-yl}pyridine-3- carbonitrile +++ [00034] 4-[5-(benzyloxy)-2,3-dihydro-1H- isoindol-2-yl]pyrimidine-5- carbonitrile +++ [00035] 4-{5-[(5-hydroxypyridin-2- yl)methoxy]-2,3-dihydro-1H- isoindol-2-yl}pyrimidine-5- carbonitrile +++ [00036] 6-{5-[(5-methoxypyridin-2- yl)methoxy]-2,3-dihydro-1H- isoindol-2-yl}-2-methyl-2,3- dihydropyridazin-3-one +++ [00037] 5-[(5-methoxypyridin-2- yl)methoxy]-2-(pyridin-4-yl)-2,3- dihydro-1H-isoindol-1-one +++

[0200] Various modifications, additions, substitutions, and variations to the illustrative examples set forth herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.